XXXX , nasal polyps, and @entity117 sensitivity: @entity244 .

@entity1 @entity1712 @entity32 @entity565 @entity117 @entity1030 @entity1800 @entity56 @entity244 @entity113 @entity1412 @entity110 @entity288
The historic triad of @entity565 , @entity1412 , and intolerance to @entity117 and related chemicals, recently designated as @entity244 , is an inflammatory condition of unknown etiology and pathogenesis. The condition is probably acquired, perhaps secondary to a @entity1800 , but a hereditary factor may be important in some @entity1 . Most @entity1 with this syndrome are adults, with an occasional case being identified in a teenager or older @entity1 . Although not every @entity1 will have the fully developed syndrome, the typical @entity1 will have all three of the classic features. Many @entity1 with @entity244 also have a marked @entity1712 of both bronchial and nasal secretions as well as the circulating blood. Approximately 10 per cent of the @entity1 have @entity110 and/or @entity113 , alone or in combination with @entity32 . The diagnosis usually can be established easily on the basis of the history and physical examination, and only rarely in clinical practice is it necessary to perform a confirmatory @entity117 challenge test. As with all @entity56 , the cornerstone of treatment is environmental control with avoidance of respiratory irritants, @entity117 , and @entity117 -like medications. Management of upper @entity1030 requires careful prescription of medication supplemented by judicious selection of surgery. A variety of medications, including bronchodilators and @entity288 , can be used to treat the bronchial symptoms. The results of current research are expected to lead to better understanding followed by further improvements in treatment for @entity1 with @entity244 .
